Article
Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.
PloS one - 1 Jan 2012
Hecht Randy, Li Yue-Sheng, Sun Jeonghoon, Belouski Ed, Hall Michael, Hager Todd, Yie Junming, Wang Wei, Winters Dwight, Smith Stephen, Spahr Chris, Tam Lei-Ting, Shen Zhongnan, Stanislaus Shanaka, Chinookoswong Narumol, Lau Yvonne, Sickmier Allen, Michaels Mark Leo, Boone Thomas, Véniant Murielle M, Xu Jing
Abstract excerpt
Fibroblast growth factor 21 (FGF21) is a promising drug candidate for the treatment of type 2 diabetes. However, the use of wild type native FGF21 is challenging due to several limitations. Among these are its short half-life, its susceptibility to in vivo proteolytic degradation and its propensity to in vitro aggregation. We here describe a rationale-based protein engineering approach to generate a potent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.